CRISPR/Cas System in Human Genetic Diseases
DOI:
https://doi.org/10.54097/ztchmw71Keywords:
CRISPR/Cas, Gene editing, Human disease, Genetic disease.Abstract
Clustered regularly interspaced short palindromic repeats/CRISPR-associated CRISPER/Cas system, as the current most popular gene-editing technology, shows great advantages of simple composition, good specificity and high cutting efficiency compared with other gene editing technology. With the rapid development of CRISPR-Cas systems, such as Cas9, Cas12a and Cas12f, can be used to edit the DNA of eukaryotic cells, and then successively found that Cas13a, Cas13b and Cas13d are targeted to the RNA merons. Through various modifications, scientists also developed a new type of the CRISPR-Cas system. With higher DNA-cutting activity, greater specificity, and smaller size than the natural CRISPR system, these engineered gene-editing systems form a powerful tool set for DNA sequence knockout, replacement, epigenetic editing, and even the activation and suppression of gene expression. Despite the potential problems in the practical application of CRISPR technology to be solved, it is believed that with further improvement, the CRISPR treatment technology will play a more important role in the prevention and treatment of human diseases, more perfectly and precisely. This review introduces the structure, functional mechanism and application of CRISPR/Cas system in human genetic diseases, and the current status and development of CRISPR/Cas system are summarized and prospected.
Downloads
References
Jiang F, Doudna JA. CRISPR-Cas9 Structures and Mechanisms. Annu Rev Biophys. 2017 May 22;46:505-529.
Charpentier E, Doudna JA. Biotechnology: Rewriting a genome. Nature. 2013 Mar 7;495(7439):50-1.
Dominguez AA, Lim WA, Qi LS. Beyond editing: repurposing CRISPR-Cas9 for precision genome regulation and interrogation. Nat Rev Mol Cell Biol. 2016 Jan;17(1):5-15.
Zhu Y. Advances in CRISPR/Cas9. Biomed Res Int. 2022 Sep 23;2022:9978571.
Shah SZ, Rehman A, Nasir H, Asif A, Tufail B, Usama M, Jabbar B. Advances In Research On Genome Editing Crispr-Cas9 Technology. J Ayub Med Coll Abbottabad. 2019 Jan-Mar;31(1):108-122.
Wyman C, Kanaar R. DNA double-strand break repair: all's well that ends well. Annu Rev Genet. 2006;40:363-83.
Ghaemi A, Bagheri E, Abnous K, Taghdisi SM, Ramezani M, Alibolandi M. CRISPR-cas9 genome editing delivery systems for targeted cancer therapy. Life Sci. 2021 Feb 15;267:118969.
Manghwar H, Lindsey K, Zhang X, Jin S. CRISPR/Cas System: Recent Advances and Future Prospects for Genome Editing. Trends Plant Sci. 2019 Dec;24(12):1102-1125.
Gaj T, Gersbach CA, Barbas CF 3rd. ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering. Trends Biotechnol. 2013 Jul;31(7):397-405.
Puchta H. Applying CRISPR/Cas for genome engineering in plants: the best is yet to come. Curr Opin Plant Biol. 2017 Apr;36:1-8.
Chavez, M., Chen, X., Finn, P.B. et al. Advances in CRISPR therapeutics. Nat Rev Nephrol19, 9–22 (2023).
Devi, V., Harjai, K. & Chhibber, S. CRISPR-Cas systems: role in cellular processes beyond adaptive immunity. Folia Microbiol 67, 837–850 (2022).
Xu, Y., & Li, Z. (2020). CRISPR-Cas systems: Overview, innovations and applications in human disease research and gene therapy. Computational and structural biotechnology journal, 18, 2401–2415.
Makarova, K.S., Wolf, Y.I., Iranzo, J., Shmakov, S.A., Alkhnbashi, O.S., Brouns, S.J.J., Charpentier, E., Cheng, D., Haft, D.H., Horvath, P., Moineau, S., Mojica, F.J.M., Scott, D., Shah, S.A., Siksnys, V., Terns, M.P., Venclovas, Č., White, M.F., Yakunin, A.F. and Yan, W. (2019). Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. Nature Reviews Microbiology, [online] 18(2), pp.67–83.
Chaudhuri, A., Halder, K. and Datta, A. (2022). Classification of CRISPR/Cas system and its application in tomato breeding. Theoretical and Applied Genetics, 135(2), pp.367–387.
Wu, S.-S., Li, Q.-C., Yin, C.-Q., Xue, W. and Song, C.-Q. (2020). Advances in CRISPR/Cas-based Gene Therapy in Human Genetic Diseases. Theranostics, [online] 10(10), pp.4374–4382.
Papizan, J.B., Porter, S.N., Sharma, A. and Pruett-Miller, S.M. (2021). Therapeutic gene editing strategies using CRISPR-Cas9 for the β-hemoglobinopathies. Journal of Biomedical Research, [online] 35(2), pp.115–134.
Mayo Clinic (2022). Sickle Cell Anemia - Symptoms and Causes. [online] Mayo Clinic. Available at: https://www.mayoclinic.org/diseases-conditions/sickle-cell-anemia/symptoms-causes/syc-20355876.
Kumaran, N., Pennesi, M.E., Yang, P., Trzupek, K.M., Schlechter, C., Moore, A.T., Weleber, R.G. and Michaelides, M. (1993). Leber Congenital Amaurosis / Early-Onset Severe Retinal Dystrophy Overview. [online] PubMed. Available at: https://www.ncbi.nlm.nih.gov/books/NBK531510/.
Mellen, R.W., Calabro, K.R., K. Tyler McCullough, Crosson, S.M., Alejandro, Fajardo, D., Xu, E., Boye, S.L. and Boye, S.L. (2023). Development of an AAV-CRISPR-Cas9-based treatment for dominant cone-rod dystrophy 6. [online] 30, pp.48–64.
Elangkovan, N., & Dickson, G. (2021). Gene Therapy for Duchenne Muscular Dystrophy. Journal of neuromuscular diseases, 8(s2), S303–S316.
Happi Mbakam, C., Lamothe, G., Tremblay, G. et al. CRISPR-Cas9 Gene Therapy for Duchenne Muscular Dystrophy. Neurotherapeutics 19, 931–941 (2022).
Wong, T. W. Y., & Cohn, R. D. (2017). Therapeutic Applications of CRISPR/Cas for Duchenne Muscular Dystrophy. Current gene therapy, 17(4), 301–308.
Arockiaraj, A. I., Johnson, M. A., Munir, A., Ekambaram, P., Lucas, P. C., McAllister-Lucas, L. M., & Kemaladewi, D. U. (2023). CRISPRa-induced upregulation of human LAMA1 compensates for LAMA2 -deficiency in Merosin-deficient congenital muscular dystrophy. bioRxiv : the preprint server for biology, 2023.03.06.531347.
Shao, Y., Wang, L., Guo, N., Wang, S., Yang, L., Li, Y., Wang, M., Yin, S., Han, H., Zeng, L., Zhang, L., Hui, L., Ding, Q., Zhang, J., Geng, H., Liu, M., & Li, D. (2018). Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats. The Journal of biological chemistry, 293(18), 6883–6892.
Ibraheim, R., Tai, P.W.L., Mir, A. et al. Self-inactivating, all-in-one AAV vectors for precision Cas9 genome editing via homology-directed repair in vivo. Nat Commun 12, 6267 (2021).
Da Silva Sanchez, A., Paunovska, K., Cristian, A., & Dahlman, J. E. (2020). Treating Cystic Fibrosis with mRNA and CRISPR. Human gene therapy, 31(17-18), 940–955.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
